- Zealand Pharma (CPH: ZEAL) shares fell more than 20% after new data raised concerns about its obesity drug partner program.
- The sell-off was linked to side effects and a high dropout rate in a late-stage trial of survodutide.
- Survodutide still showed strong weight-loss results, but investors are worried about whether patients will stay on the drug.
- The obesity drug market is huge, but competition from Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) is intense.
- For investors, Zealand Pharma now looks higher risk until the company can rebuild confidence.
Zealand Pharma (CPH: ZEAL) shares slumped after investors reacted badly to new clinical trial data for survodutide, an experimental weight-loss drug being developed with privately owned Boehringer Ingelheim.
The Danish biotech stock fell more than 20%, with reports showing a decline of roughly 22% to 24% during European trading. The drop came after the data showed a high number of patients stopped using the drug because of stomach-related side effects.
For investors, this is a big deal. The weight-loss drug market is one of the hottest areas in global healthcare. But the market is also very competitive. A drug does not just need to help people lose weight. It also needs to be safe, easy to tolerate and strong enough to compete with products from Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO).
Why Zealand Pharma shares fell
The problem was not that survodutide failed to help people lose weight.
In fact, Boehringer Ingelheim and Zealand Pharma said the drug helped patients lose up to 16.6% of body weight after 76 weeks in a Phase 3 trial. That is a meaningful result.
The issue is tolerability.
New data showed that about 19% of patients stopped treatment because of gastrointestinal side effects, compared with about 2.9% on placebo. These side effects can include problems such as nausea, vomiting and diarrhoea.
That worried investors because weight-loss drugs are often taken for a long time. If too many patients stop taking the drug, doctors may be less likely to prescribe it and insurers may be less willing to support broad use.
In simple terms, the market is asking one question: even if the drug works, will enough people be able to stay on it?
Why the obesity market matters
The obesity treatment market has become one of the biggest growth opportunities in healthcare.
Eli Lilly and Novo Nordisk have already built strong positions with drugs such as Zepbound, Mounjaro, Wegovy and Ozempic. These companies have set a very high bar for new competitors.
That is why Zealand Pharma’s sell-off was so sharp. Investors were hoping survodutide could become a serious challenger in the obesity market. The latest data does not kill that hope, but it does make the story more complicated.
Survodutide is designed as a dual-acting drug that targets both GLP-1 and glucagon receptors. That could give it a different profile from existing medicines. It has also shown potential benefits beyond weight loss, including improvements in body weight and other metabolic measures.
Those are positives. But the side-effect profile now looks like the key concern.
What this means for investors
Zealand Pharma is not finished. The company still has a valuable partnership with Boehringer Ingelheim, a pipeline of obesity and metabolic disease programs, and potential future milestone and royalty income if survodutide reaches the market.
But the risk has clearly gone up.
Biotech investing is very different from buying a mature blue-chip company. Share prices can move sharply on trial results, safety data and analyst expectations. A single update can add or wipe out billions in market value.
For investors who already own Zealand Pharma, the key question is whether this sell-off is an overreaction or the start of a deeper reset in expectations.
For new investors, patience may be smarter than chasing the dip. The company needs to show that survodutide can still compete in a crowded market and that doctors will accept the side-effect trade-off.
Bottom line
Zealand Pharma’s share price fall shows how tough the obesity drug race has become.
Survodutide still has promise, and the weight-loss results are not weak. But in this market, effectiveness alone is not enough. Patients need to tolerate the drug, and investors need confidence that it can compete with the biggest names in the sector.
For now, Zealand Pharma remains a high-risk biotech stock. The opportunity is large, but after this data, the market will want more proof before turning positive again.
